You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 9,107,912


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,107,912
Title:Methods for concomitant treatment of theophylline and febuxostat
Abstract: The present disclosure relates to a method of treating hyperuricemia in a patient that also suffers from a second disease state requiring treatment with theophylline, wherein the patient receives concomitant treatment with a xanthine oxidoreductase inhibitor and theophylline without resulting in theophylline toxicity to the patient and without substantial adjustments to the manufacturer's recommended dosage of theophylline.
Inventor(s): Gunawardhana; Lhanoo (Pleasant Prairie, WI), Tsai; Max (Highland Park, IL), Naik; Himanshu (Evanston, IL)
Assignee: Takeda Pharmaceuticals U.S.A., Inc. (Deerfield, IL)
Application Number:13/227,828
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,107,912
Patent Claims: 1. A method of treating hyperuricemia in a patient in need of treatment thereof, the method comprising the steps of: administering to a patient suffering from hyperuricemia and at least one second disease state, a therapeutically effective amount of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid or a pharmaceutically acceptable salt thereof, wherein the subject is also receiving concomitant administration of theophylline to treat the at least one second disease state, and further wherein (i) the administration of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid or a pharmaceutically acceptable salt thereof, to the patient does not result in theophylline toxicity to the patient; and (ii) administration of the theophylline is in an amount ranging from about 90% to about 110% of a manufacturer's recommended theophylline dosage amount in the absence of administration of at least one xanthine oxidoreductase inhibitor.

2. The method of claim 1, wherein the second disease state is asthma.

3. The method of claim 1, wherein the patient is further suffering from at least one third disease state, wherein the third disease is gout.

4. The method of claim 1, wherein the theophylline dosage amount ranges from about 95% to about 105% of a manufacturer's recommended theophylline dosage amount in the absence of administration of at least one xanthine oxidoreductase inhibitor.

5. The method of claim 1, wherein the theophylline dosage amount ranges from about 99% to about 101% of a manufacturer's recommended theophylline dosage amount in the absence of administration of at least one xanthine oxidoreductase inhibitor.

6. The method of claim 1, wherein the patient suffering from hyperuricemia and the at least one second disease state is previously administered theophylline prior to initiation of treatment with 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.